Clinical Trials Directory

Trials / Completed

CompletedNCT02711306

Effects of Konjac Glucomannan Noodle Intervention in Subjects With Metabolic Syndrome

Office of Human Research, Taipei Medical University

Status
Completed
Phase
N/A
Study type
Interventional
Enrollment
36 (actual)
Sponsor
Taipei Medical University · Academic / Other
Sex
All
Age
20 Years – 64 Years
Healthy volunteers
Not accepted

Summary

Metabolic syndrome (MS) is a complex disease with a cluster of risk factors and clinical features, which includes central or abdominal obesity, atherogenic dyslipidemia, impaired glucose regulation, hyperinsulinemia, high blood pressure, and concomitance of pro-inflammatory cytokine and insulin resistance. Glucomannan (GM) is a water-soluble dietary fiber derived from the root of Amorphophallus konjac that can improve blood sugar, blood fat concentration, and weight management, and has other health benefits.The purposes of this study are going to investigate the effects of KGM noodle (KGN) as stable food to MS and diabetic patients.

Detailed description

The KGN diet was composed of well-cooked noodle with 2 g of KGM in a dosage of 200 g/piece twice daily to substitute the daily carbohydrate for 4 weeks, with a 2-week washout period between alternative diets. All 33 subjects received two servings of either GMNs or PNs (400 g) per day, which replaced the main carbohydrate in two daily meals for 4 weeks. After a 2-week washout period, the subjects received the other type of noodle for 4 weeks. The body weight, BMI, waist circumference, fasting blood glucose and lipid profile, as well as serum vitamin A, E, β-carotene and high sensitivity C-reactive protein (hs-CPR) were measured by HPCL.

Conditions

Interventions

TypeNameDescription
DIETARY_SUPPLEMENTGlucomannan noodleThe participants received two servings (400 g) of GMN every day to replace their daily carbohydrate intake for 4 weeks.
DIETARY_SUPPLEMENTPlacebo noodleIn the placebo noodle diet, the participants received the same amount of noodles without glucomannan for 4 weeks.

Timeline

Start date
2013-05-01
Primary completion
2014-01-01
Completion
2014-03-01
First posted
2016-03-17
Last updated
2019-10-29
Results posted
2019-10-29

Source: ClinicalTrials.gov record NCT02711306. Inclusion in this directory is not an endorsement.